查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790335

头颈癌治疗市场规模、份额和趋势分析报告：按治疗类型、给药途径、分销管道、地区和细分市场预测，2025-2033 年

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

头颈癌治疗市场概况

2024 年全球头颈癌治疗市场价值估计为 22.7 亿美元，预计到 2033 年将达到 62.5 亿美元，2025 年至 2033 年的复合年增长率为 11.95%。由于头颈癌发病率上升、对标靶治疗治疗和免疫治疗的需求不断增加以及诊断准确性的提高等因素，市场正在扩大。

2025 年 6 月，GORTEC 的 III 期 REACH 研究表明，对于合格接受Cisplatin的头颈癌患者， Avelumab合併放射治疗取得了积极成果。该研究达到了延长无恶化生存期的主要终点，并在 500 多名入组患者中证明了良好的安全性。患者和临床医生对个人化癌症医疗的认识不断提高，正在加速早期诊断和多重药物联合治疗的采用。向毒性较低的微创治疗的转变正在推动临床对新型药物的偏好。扩大临床试验和加速监管核准正在提高主要市场的产品可得性。

人类乳突病毒 (HPV) 相关口咽癌的盛行率不断上升，已成为头颈癌治疗市场的主要驱动力。这些 HPV 相关亚型对治疗的反应通常不同，促使相关研究和定製药物的开发日益增加。临床指引越来越多地根据 HPV 状态区分治疗方法，从而推动了精准医疗的需求。製药公司正在投资针对病毒致癌转化的治疗方案，拓宽治疗前景。年轻成人 HPV 阳性患者的增加正在改变疾病的人口结构，并创造新的市场机会。大众对 HPV 相关恶性肿瘤的认识提高和筛检有助于更早诊断和开始治疗。

在头颈癌治疗领域，联合治疗策略的应用势头强劲，可望提高缓解率和存活率。免疫疗法与化疗或标靶药物结合的治疗方法正在第一线治疗和难治性治疗中进行测试。例如，2025年6月，FDA核准Keytruda用于治疗PD-L1阳性头颈癌患者，凸显了人们对生物标记引导治疗日益增长的关注。该公告也强调了PD-L1阴性患者尚未满足的需求。 CEL-SCI的Multikine旨在透过在标准治疗之前对患者进行治疗（无论PD-L1状态如何）来弥补这一缺口。 Multikine旨在刺激早期免疫反应，是一种新颖的治疗方法，可扩大治疗的可及性并改善不同患者群体的预后。

目录

第一章调查方法与范围

第二章执行摘要

第三章头颈癌治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

4. 头颈癌治疗市场：治疗类型业务分析

  • 2024 年和 2033 年治疗类型市场占有率
  • 治疗类型细分仪表板
  • 按治疗类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 化疗
  • 免疫疗法
  • 标靶治疗

5. 头颈癌治疗市场：给药途径业务分析

  • 2024年及2033年给药途径市场占有率
  • 给药途径细分仪表板
  • 2021 年至 2033 年按管理途径分類的市场规模、预测与趋势分析
  • 注射
  • 口服

6. 头颈癌治疗市场：通路业务分析

  • 2024年及2033年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 零售和专业药局
  • 医院药房
  • 网路药局

第七章头颈癌治疗市场：区域、估计和趋势分析

  • 2024 年及 2033 年区域市场占有率分析
  • 区域市场仪表板
  • 2021-2033年市场规模与预测趋势分析
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Eli Lilly and Company
    • Sanofi
    • Merck & Co., Inc.
    • Cumberland Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Summary

The global head and neck cancer therapeutics market size was estimated at USD 2.27 billion in 2024 and is projected to reach USD 6.25 billion by 2033, growing at a CAGR of 11.95% from 2025 to 2033. The market is growing due to the rising incidence of head and neck cancers, increasing demand for targeted and immunotherapy-based treatments, and advancements in diagnostic precision.

In June 2025, GORTEC's Phase III REACH trial showed positive results for avelumab plus radiotherapy in head and neck cancer patients ineligible for cisplatin. The trial met its primary endpoint of improved progression-free survival and demonstrated a favorable safety profile across over 500 enrolled patients. Growing awareness among patients and clinicians regarding personalized oncology care is accelerating early diagnosis and multi-line therapy adoption. The shift toward minimally invasive treatment options with reduced toxicity drives clinical preference for novel drug classes. Expansion of clinical trials and faster regulatory approvals are enhancing product availability across key markets.

The growing prevalence of human papillomavirus (HPV)-associated oropharyngeal cancers is emerging as a significant driver in the head and neck cancer therapeutics market. These HPV-related subtypes often respond differently to treatment, prompting a rise in research and tailored drug development. Clinical guidelines increasingly differentiate therapeutic approaches based on HPV status, fueling demand for precision therapies. Pharmaceutical companies are investing in treatment protocols that address viral oncogenesis, expanding the therapeutic landscape. The increasing incidence of HPV-positive cases among younger adults has shifted the disease demographic, creating new market opportunities. Enhanced public awareness and screening for HPV-related malignancies contribute to earlier diagnosis and treatment initiation.

Adopting combination therapy strategies is gaining momentum in the head and neck cancer therapeutics space, offering improved response rates and survival outcomes. Treatment regimens integrating immunotherapy with chemotherapy or targeted agents are being tested in both first-line and refractory settings. For instance, in June 2025, the FDA approved Keytruda for PD-L1-positive head and neck cancer patients, highlighting the growing focus on biomarker-based therapies. The announcement also emphasized the unmet need in PD-L1-negative patients. CEL-SCI's Multikine aims to address this gap by treating patients before standard therapies, regardless of PD-L1 status. Designed to stimulate an early immune response, Multikine represents a novel approach that could broaden treatment access and improve outcomes across diverse patient groups.

Global Head And Neck Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global head and neck cancer therapeutics market report based on therapy type, route of administration, distribution channel, and region:

  • Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Injectable
  • Oral
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail and Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy Type
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Head and Neck Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

  • 4.1. Therapy Type Market Share, 2024 & 2033
  • 4.2. Therapy Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy Type, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2033
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market, 2021 - 2033 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 6. Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Retail and Specialty Pharmacies
    • 6.4.1. Retail and Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Head and Neck Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Route of Administration Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Route of Administration Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Route of Administration Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Route of Administration Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Route of Administration Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Route of Administration Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Route of Administration Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Route of Administration Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Route of Administration Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Route of Administration Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Route of Administration Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Route of Administration Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Route of Administration Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Route of Administration Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Route of Administration Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Route of Administration Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Route of Administration Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Route of Administration Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Route of Administration Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Route of Administration Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Route of Administration Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Route of Administration Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Route of Administration Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Eli Lilly and Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Therapy Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Sanofi
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Therapy Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Therapy Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cumberland Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Therapy Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bristol-Myers Squibb Company
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Therapy Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AstraZeneca
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Therapy Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda Pharmaceutical Company Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Therapy Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Therapy Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Therapy Type Benchmarking
      • 8.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global head and neck cancer therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 5 Global head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 6 Global head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 9 North America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 10 North America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 12 U.S. head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 13 U.S. head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 15 Canada head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 Canada head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 18 Mexico head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 19 Mexico head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 22 Europe head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 23 Europe head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 25 UK head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 26 UK head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 28 Germany head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Germany head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 31 France head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 32 France head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 34 Italy head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 35 Italy head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 37 Spain head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 38 Spain head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 40 Norway head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 Norway head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 43 Denmark head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 44 Denmark head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 46 Sweden head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 47 Sweden head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD
  • Table 50 Asia Pacific head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 53 Japan head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 54 Japan head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 56 China head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 China head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 59 India head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 60 India head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 62 Australia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 63 Australia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 65 South Korea head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 South Korea head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 68 Thailand head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 69 Thailand head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 72 Latin America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 73 Latin America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 75 Brazil head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 76 Brazil head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 78 Argentina head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 79 Argentina head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 85 South Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 91 UAE head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 92 UAE head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait head and neck cancer therapeutics market, by therapy type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Kuwait head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Head and neck cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Head and neck cancer therapeutics market dynamics
  • Fig. 12 Head and neck cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Head and neck cancer therapeutics market: PESTLE analysis
  • Fig. 14 Therapy type market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 19 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail and Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 25 Head and neck cancer therapeutics market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 Europe Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 MEA Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework